Abstract Aim: @entity11529 ( @entity11529 ) are neoplastic proliferations of endothelial cells which occur with an incidence of 10-12%. @entity11529 rapidly growing and found in cosmetically sensitive areas or complicated with @entity1066 are of special concern of parents. Methods: A review of medical charts was performed for newborns treated with @entity1169 because of @entity11529 between 2012 and 2013. There were two @entity1 and two @entity1 , referred to our department at the age of 2-3 weeks. @entity1 were commenced on @entity1169 0.5   mg/kg daily and closely monitored. The dosage was increased up to a maximum of 2   mg/kg/d and was maintained until the lesion had involuted or showed good result. Results: The minimal dosage required to achieve involution was 1.5-2.0   mg/kg/d. No rebound growth or complications were observed. Three @entity1 showed excellent response with resolution of the lesion. Fourth @entity1 showed good result with >50% reduction of @entity11529 . Conclusions: @entity1169 at 1.5-2.0   mg/kg/d is effective and safe for treating @entity11529 in our series of newborn @entity1 . Treatment should be maintained until the lesion is involuted or shows good cosmetic result. Still there is need for larger scale studies confirming the safety and efficacy of @entity1169 in treatment of haemangiomas in newborns.

Treatment of rapidly proliferating haemangiomas in newborns with XXXX and review of the literature.

@entity11529 :: ('MESH:D020936', 'Disease') :: ['Infantile haemangiomas', 'IH'] @entity1 :: ('9606', 'Species') :: ['patients', 'Children', 'patient', 'girls', 'boys'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcerations'] @entity1169 :: ('MESH:D011433', 'Chemical') :: ['propranolol', 'Propranolol']
@entity1169 :: (MESH:D011433,Chemical) :: ['propranolol']
